On contrary, several in vitro studies reported that inhibition of NKCC1 could reduce cell proliferation, invasion and/or migration in glioblastoma, glioma, esophageal squamous cell carcinoma, hepatocellular carcinoma and gastric cancer cells which may indicate a global underlying tumor-inhibiting mechanism [35–41]. Here, SLC12A2 is linked to glioma.